消息面上，石四药集团此前发布公告，预计2025年度溢利将较上年度的10.61亿港元下降45%-60%。主 要由于2024年一季度国内流感爆发以致静脉输液及其他药品市场需求量旺盛，但截至2025年12月31日止 的整个年度因国内没有大规模流行病发生叠加医保控费导致药品终端销量下降；各种形式的带量采购范 围扩大以及国内外行业竞争加剧带来持续的价格压力；及盐酸溴己新安瓿注射液因不再通过国家药品集 采销售而营业额有所减少。 智通财经APP获悉，石四药集团(02005)午后跌超5%，截至发稿，跌5.34%，报2.66港元，成交额5290.44 万港元。 ...

智通财经APP获悉，石四药集团(02005)跌超7%，截至发稿，跌7.28%，报2.8港元，成交额257.58万港 元。 消息面上，石四药集团发布公告，预计2025年度溢利将较上年度的10.61亿港元下降45%-60%。主要由 于2024年一季度国内流感爆发以致静脉输液及其他药品市场需求量旺盛，但截至2025年12月31日止的整 个年度因国内没有大规模流行病发生叠加医保控费导致药品终端销量下降；各种形式的带量采购(包括 国家药品集采及地方联盟集采)范围扩大以及国内外行业竞争加剧带来持续的价格压力；及盐酸溴己新 安瓿注射液因不再通过国家药品集采销售而营业额有所减少。 ...

估计公司股权持有人应占溢利的下降主要由于以下因素导致营业额下降：(i)2024年一季度国内流感爆发 以致静脉输液及其他药品市场需求量旺盛，但截至2025年12月31日止的整个年度因国内没有大规模流行 病发生叠加医保控费导致药品终端销量下降;(ii)各种形式的带量采购(包括国家药品集采及地方联盟集 采)范围扩大以及国内外行业竞争加剧带来持续的价格压力;及(iii)盐酸溴己新安瓿注射液因不再通过国 家药品集采销售而营业额有所减少。 格隆汇2月16日丨石四药集团(02005.HK)公告，基于董事局目前可获得的资讯及对集团截至2025年12月 31日止年度的未经审核管理账目所作出的初步审阅後，董事局初步估计，截至2025年12月31日止年度之 公司股权持有人应占溢利与截至2024年12月31日止年度之公司股权持有人应占溢利10.61亿港元相比， 集团预计将录得介乎45%至60%的下降。 ...

Core Viewpoint - The company, 石四药集团, anticipates a decline of approximately 45% to 60% in profit attributable to equity holders for the year ending December 31, 2025, compared to HKD 1.061 billion for the year ending December 31, 2024 [1] Group 1: Profit Forecast - The estimated decline in profit is primarily due to a decrease in revenue caused by several factors, including the lack of large-scale epidemics in the domestic market and healthcare cost control measures leading to reduced drug sales [1] - The company expects that the expansion of various forms of bulk purchasing, including national and local drug procurement, along with intensified competition, will continue to exert price pressure [1] - Revenue from the product, 盐酸溴己新安瓿注射液, has decreased as it is no longer sold through national drug procurement [1] Group 2: Financial Health and Strategy - Despite the anticipated decline in profit, the company's financial position and cash flow remain robust [1] - The company has been focusing on product diversification in recent years, enhancing sales of oral formulations and active pharmaceutical ingredients to optimize its product mix [1] - The company is actively taking appropriate measures to seek improvements in performance, while closely monitoring the situation and responding in a timely manner as it progresses into 2026 [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, anticipates a significant decline in profit attributable to equity holders, projecting a decrease of approximately 45% to 60% compared to HKD 1.061 billion for the year ending December 31, 2024 [1] Group 1: Profit Forecast - The estimated decline in profit is primarily due to a decrease in revenue driven by several factors, including the absence of large-scale epidemics and healthcare cost control measures leading to reduced drug sales [1] - The company expects that the absence of major epidemics, which previously boosted demand for intravenous infusions and other medications, will negatively impact sales for the year ending December 31, 2025 [1] - Increased price pressure from expanded volume-based procurement initiatives and intensified competition in both domestic and international markets is also contributing to the anticipated revenue decline [1] Group 2: Financial Health and Strategy - Despite the expected decline in profit, the company's financial position and cash flow remain robust [1] - The company has been focusing on product diversification in recent years, enhancing sales of oral formulations and active pharmaceutical ingredients to optimize its product mix [1] - The company is actively taking appropriate measures to seek improvements in performance, while closely monitoring the situation and responding in a timely manner as it progresses into 2026 [1]

Core Viewpoint - The company reported a significant decline in revenue and profit for the nine months ending September 30, 2025, primarily due to decreased sales in intravenous infusion and ampoule injection products, alongside intensified price pressures from expanded procurement initiatives and increased competition in the industry [1] Financial Performance - The company's unaudited revenue for the nine months ending September 30, 2025, was approximately HKD 3.102 billion, representing a year-on-year decrease of 31.6% [1] - The unaudited gross profit for the same period was approximately HKD 1.294 billion, down 46.1% year-on-year, with a gross profit margin of 41.7%, a decline of 11.3 percentage points compared to the previous year [1] - The unaudited profit attributable to shareholders for the nine months was approximately HKD 399 million, reflecting a year-on-year decrease of 56.6% [1]

Core Viewpoint - The company reported a significant decline in revenue and profit for the nine months ending September 30, 2025, primarily due to decreased sales in intravenous infusion and ampoule injection products, alongside intensified price pressures from expanded procurement initiatives and increased competition in the industry [1] Financial Performance - The company's unaudited revenue for the nine months was approximately HKD 3.102 billion, representing a year-on-year decrease of 31.6% [1] - The unaudited gross profit for the same period was approximately HKD 1.294 billion, down 46.1% year-on-year, with a gross profit margin of 41.7%, a decline of 11.3 percentage points compared to the previous year [1] - The unaudited profit attributable to shareholders for the nine months was approximately HKD 399 million, reflecting a year-on-year decrease of 56.6% [1]